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| BACKGROUND
Atrial fibrillation (AF) is the most common arrhythmia in the United States. It is characterized by rapid and disorganized atrial activity increases the risk of heart failure (HF) and stroke, and reduce quality of life. 1 The risk of stroke increases up to 20-fold in patients with AF compared to those in sinus rhythm. 2 Optimizing anticoagulant therapy in patients with AF is essential to reduce the risk of thromboembolic events and improve quality of life. The 2014 American Heart Association/American College of Cardiology/Heart Rhythm Society Guidelines for the Management of Patients With Atrial Fibrillation recommend that the CHA 2 DS 2 -VASc score be used to assess stroke risk and guide choice of anticoagulant therapy. 3 For patients with risk factors such as congestive HF, diabetes mellitus, or previous stroke, warfarin or a direct oral anticoagulant (DOAC), such as dabigatran, rivaroxaban, or apixaban (guideline recommendation 1A and 1B, respectively) is recommended. However, the choice of anticoagulation is not a one-size-fits-all approach. Other factors such as renal and hepatic function, ability to maintain a therapeutic international normalized ratio, availability of a reversal agent, bleeding risk, and food and drug interactions must be considered when choosing the most appropriate agent for stroke prevention in AF.
Strategies to control symptoms from AF and prevent cardiac remodeling and hypertrophy include rate and/or rhythm control agents. 3 Rate control agents have similar outcomes on hospitalizations and mortality compared to rhythm control agents, with fewer side effects. 4 Patients often require the addition of rhythm control agents (also known as antiarrhythmic drugs) when symptoms become intolerable or the patient's heart rate cannot be adequately controlled with rate control agents. Many rhythm control agents have the potential for significant drug-drug interactions with oral anticoagulants and thus make management difficult.
Several pharmacokinetic studies have shown varying results about in vitro interactions with oral anticoagulants. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] Most oral anticoagulants are primarily metabolized via multiple cytochrome P450 (CYP) enzymes and/or P-glycoprotein and may be susceptible to drug-drug interactions. A pharmacokinetics study by Wang and colleagues 5 showed the metabolic drug-drug interaction potential between apixaban and other coadministered medications is low. In contrast, other studies have shown that coadministration of apixaban with either strong CYP3A4 inhibitors (diltiazem and ketoconazole) or drugs that increase its bioavailability may cause up to a 2-fold increase in the area under the curve of apixaban. 6, 7 Similar concerns exist with warfarin. Two studies have demonstrated that administration of amiodarone, a potent CYP3A4 inhibitor, with warfarin reduced the clearance of warfarin. 8, 9 The clinical significance of this interaction with DOACs warrants further assessment.
To date, no real-world data exist on clinical outcomes of concurrent use of apixaban and concomitant antiarrhythmic drugs. A subgroup analysis from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial evaluated patients in both study groups (warfarin or apixaban) on concomitant amiodarone and found a similar rate of thromboembolic events (1.24%/year for apixaban vs. 1.85%/year for warfarin; hazard ratio
[HR], 0.68; 95% confidence interval [CI], 0.40-1.15) but a higher rate of major bleeding events (2.18%/year for apixaban vs. 3.03%/year for warfarin; HR, 0.72; 95% CI, 0.62-0.84). 15 A separate subgroup analysis, however, showed no significant difference in both rates of thromboembolic events and major bleeding events in either group. 16 Another subgroup analysis demonstrated an increased risk of thromboembolic events and major bleeding with increased number of concomitant medications in both warfarin and apixaban groups. 17 However, apixaban was still more effective as compared to warfarin, while in terms of major bleeding, its benefits decreased with increasing number of concomitant drugs. A study in Taiwan found an increased bleeding risk in patients with nonvalvular atrial fibrillation (NVAF) taking a DOAC along with amiodarone, fluconazole, rifampin, or phenytoin (medications with a common metabolic pathway) compared to a DOAC alone. 18 Several pivotal comparative studies demonstrated the superiority or noninferiority of DOACs over warfarin. However, none of these studies have addressed the safety and effectiveness outcomes of concomitant rhythm control agents. With the high prevalence of AF patients on antiarrhythmic medications, specifically amiodarone, Conclusion: Apixaban was associated with reduced stroke/systemic embolism and bleeding when compared with warfarin. No difference was seen in thrombotic or bleeding events in patients on concurrent antiarrhythmic medications.
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Essentials
• No real-world data exist in patients on anticoagulants and concomitant antiarrhythmic drugs.
• A retrospective cohort study was conducted using a US electronic medical record database (2012-2016).
• A total of 20 378 patients were included in this propensity matched analysis.
• There was no difference in thrombosis or bleeding in patients on concurrent antiarrhythmic medications.
patients on warfarin may be at risk of worse outcomes compared to patients on apixaban. With 2.5 million Americans suffering from AF, of which 20% receive a concurrent antiarrhythmic medication, this represents a large portion of patients on high-risk pharmacotherapy. 19 Using a large national electronic medical record (EMR) database of patients, this study aimed to compare the safety and effectiveness of apixaban and warfarin, first in patients with NVAF and then in patients on concomitant antiarrhythmic medications.
| METHODS

| Data source, study design, and sample
The GE Centricity EMR database is a real-world observational, daily- Incident and prevalent users were identified using the washout period. Inclusion criteria required patients to be continuously enrolled 1 year before and 1 year after the index date, defined as patients having at least 1 office visit in the 12 months prior to index date and in the 12 months after the study.
Patients were excluded from the study if they were pregnant, had valvular heart disease, venous thromboembolism, cardiac surgery, pericarditis, or thyrotoxicosis within the 12 months prior to the index date. Additionally, patients were excluded if they used rivaroxaban, edoxaban, or dabigatran during the study period.
The primary independent variable was prescription of either apixaban or warfarin. The primary outcome variables were efficacy and safety. The primary efficacy endpoint was identified using
International Classification of Diseases, Ninth Revision (ICD-9) or 10th
Revision (ICD-10) codes for stroke (ischemic or hemorrhagic) or systemic embolism during the follow-up period. The primary safety outcome was identified using ICD-9 and ICD-10 codes for bleeding during the follow-up period. It was defined as symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome, and/or bleeding causing a fall in hemoglobin level of ≥2 g/dL or leading to transfusion of ≥2 units of whole blood or red cells (International Society of Thrombosis and Hemostasis definition).
| Statistical analysis
Descriptive statistics were provided for baseline sample characteristics. T test and chi-square were performed to assess the group difference for continuous and categorical variables, respectively.
One-to-one propensity score matching was conducted to reduce the impact of treatment-selection bias. 12 months prior to the index date, and these patients were also incident users of anticoagulation therapy, as defined in the primary analysis. The patients were followed for 1 year after the index date.
One-to-one propensity score matching was also conducted in the subgroup analysis. McNemar chi-square test for the matched-pair cohort was performed to assess the association between treatment exposure and risk of bleeding for the 1-year follow-up period. Cox regression analysis was performed for the matched data to compare the risk of stroke of patients taking apixaban vs. warfarin and concurrent antiarrhythmic medication.
All statistical analyses were performed using SAS version 9.3 (SAS Institute, Cary, NC) statistical package at a priori significance level of 0.05.
| RESULTS
A total of 332 100 patients were identified as having a diagnosis of AF. Among these, 146 294 patients were prescribed either warfarin or apixaban. After applying the washout period of 12 months, a total of 47 100 incident users of warfarin or apixaban were identified.
Among those incident users, 36 538 patients had at least 1 physician visit 1 year prior to the index date and at least 1 physician visit 1 year after the index date. After applying the exclusion criteria, the final cohort consisted of 31 612 incident users of warfarin or apixaban.
Of these, 21 319 were incident users of warfarin and 10 293 were incident users of apixaban. The cohort identification process is summarized in Figure 1 .
Results of baseline sample characteristics for the matched cohort are presented in Table 1 . After propensity score matching, the matched cohort consisted of 20 378 patients, 10 189 patients in the apixaban group and 10 189 in the warfarin group. A total of 121 (1.20%) of patients in the apixaban group experienced stroke or systemic embolism, compared to 167 (1.63%) of patients in the warfarin group (HR, 0.84; 95% CI, 0.79-0.88) ( Figure 2 ). In patients with covariates that differed at baseline between the 2 groups (dyspepsia, renal disease, or HAS-BLED score), there was no difference in stroke or systemic embolism seen ( 
| Antiarrhythmic medication subgroup analysis results
A total of 3774 patients with concomitant apixaban or warfarin and antiarrhythmic drug use were identified. After propensity score matching, the matched cohort consisted of 2496 patients, 1248 in the apixaban group and 1248 in the warfarin group ( Figure 3 ; Table 4 ). Among the matched cohort, there were 13 (1.04%) strokes in the apixaban group compared to 17 (1.37%) in the warfarin group (P = 0.42). No patient in the subgroup experienced a systemic embolism. Regarding bleeding outcomes, 66 (5.29%) patients in the apixaban group and 86 (6.89%) patients in the warfarin group experienced a bleeding event (P = 0.08).
| DISCUSSION
In this national cohort of patients diagnosed with NVAF, we assessed the real-world safety and effectiveness of newly initiated apixaban compared to warfarin. We further evaluated the safety and effectiveness in those patients receiving concomitant antiarrhythmic medications. The principal findings were that, given similar baseline characteristics with propensity score matching, apixaban was associated with a reduced risk of bleeding and stroke and/or systemic embolism as compared to warfarin. Further, for patients on concomitant antiarrhythmic medications, there was no significant difference in the risk of bleeding and stroke between patients on apixaban or warfarin.
We are not aware of other national-based studies that investi- The results of the main study analyzing apixaban and warfarin only were consistent with phase 3 clinical trials as well as claimsbased observational studies. As indicated through our study findings, matched cohorts on apixaban had reduced risk of bleeding and stroke as compared to warfarin. This trend is consistent with the ARISTOTLE trial, which showed that apixaban reduced the rate of stroke or systemic embolism by 21% and major bleeding by 31% among patients with AF and at least 1 additional risk factor for stroke. 22 On a similar note, claims-based observational studies have risk of major bleeding as compared to warfarin using a US claims database. Another US-based study revealed that apixaban effectively lowered the risk of both stroke and major bleeding as compared to warfarin among patients with NVAF. 24 Superiority of apixaban over warfarin was also validated in studies carried out in Japan and Taiwan, thereby demonstrating the robustness of these results. 25, 26 The results of our subanalysis were in contrast to the ARISTOTLE trial analysis by Flaker and colleagues, which reported that AF patients on apixaban and concurrent amiodarone had a reduced rate of stroke, systemic embolism, and major bleeding as compared to patients on warfarin and concurrent amiodarone. Our study showed that for patients on concomitant antiarrhythmic medications, there was no significant difference in the risk of bleeding and stroke between apixaban and warfarin users. In the Flaker study, there was a statistically significant decrease in time in therapeutic range for patients on warfarin and concurrent amiodarone (warfa-rin+amiodarone 56.5% vs. warfarin 63%; P < 0.0001). Our study did The retrospective, observational study design has limitations that may reduce interpretation of these results as causal effects.
Uncontrolled confounding due to nonrandomized prescribing of drugs by a physician is frequent in observational studies. However, our study employed propensity score methodology to mitigate con- 
| CONCLUSION
In a large national cohort of patients with nonvalvular AF, anticoagulation with apixaban was associated with reduced risk of stroke and/or systemic embolism and bleeding events when compared with warfarin. In a subgroup analysis of patients on concurrent antiarrhythmic medications, there was no difference seen in stroke or bleeding events. Future randomized studies should assess the impact of concurrent antiarrhythmic medications on patient outcomes.
